Lars Klareskog Selected Research

Epitopes

1/2023	Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking.
1/2022	Antibodies to a Citrullinated Porphyromonas gingivalis Epitope Are Increased in Early Rheumatoid Arthritis, and Can Be Produced by Gingival Tissue B Cells: Implications for a Bacterial Origin in RA Etiology.
1/2021	The shared susceptibility epitope of HLA-DR4 binds citrullinated self-antigens and the TCR.
1/2021	Haplotype-Specific Expression Analysis of MHC Class II Genes in Healthy Individuals and Rheumatoid Arthritis Patients.
10/2018	Systematic approach demonstrates enrichment of multiple interactions between non-HLA risk variants and HLA-DRB1 risk alleles in rheumatoid arthritis.
1/2018	Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants.
1/2018	A Shared Epitope of Collagen Type XI and Type II Is Recognized by Pathogenic Antibodies in Mice and Humans with Arthritis.
5/2015	Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis.
5/2015	Associations with smoking and shared epitope differ between IgA- and IgG-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis.
5/2015	Gene-gene interaction and RNA splicing profiles of MAP2K4 gene in rheumatoid arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lars Klareskog Research Topics

Disease

194	Rheumatoid Arthritis 01/2024 - 08/2003
27	Arthritis (Polyarthritis) 03/2024 - 01/2002
24	Inflammation (Inflammations) 11/2023 - 01/2004
14	Autoimmune Diseases (Autoimmune Disease) 03/2024 - 09/2008
11	Pain (Aches) 10/2023 - 08/2014
7	Rheumatic Diseases (Rheumatism) 03/2024 - 02/2004
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020 - 09/2003
5	Necrosis 11/2023 - 01/2006
5	Arthralgia (Joint Pain) 10/2023 - 07/2013
5	Periodontitis 01/2022 - 07/2014
4	Multiple Sclerosis 01/2023 - 05/2005
4	Joint Diseases (Joint Disease) 12/2021 - 11/2010
4	Lymphoma (Lymphomas) 04/2008 - 06/2003
3	Infections 01/2024 - 01/2004
3	Synovitis 01/2022 - 01/2006
3	Experimental Arthritis 06/2009 - 01/2005
2	Obesity 10/2023 - 01/2019
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2023 - 02/2010
2	Genetic Risk Score 01/2023 - 10/2015
2	Hypersensitivity (Allergy) 01/2022 - 01/2022
2	COVID-19 12/2021 - 01/2021
2	Human Influenza (Influenza) 01/2021 - 04/2007
2	Psoriatic Arthritis 01/2021 - 11/2010
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2018 - 03/2009
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2014 - 11/2010
2	Asthma (Bronchial Asthma) 02/2010 - 02/2004
2	Myasthenia Gravis 11/2009 - 09/2008
2	Tetanus 04/2007 - 01/2007
2	Celiac Disease (Celiac Sprue) 02/2005 - 06/2002

Drug/Important Bio-Agent (IBA)

64	Proteins (Proteins, Gene)FDA Link 01/2024 - 12/2004
47	AntibodiesIBA 01/2024 - 06/2002
44	Anti-Citrullinated Protein AntibodiesIBA 01/2023 - 08/2007
37	AutoantibodiesIBA 01/2024 - 01/2004
30	Peptides (Polypeptides)IBA 11/2023 - 01/2008
25	acetyl 4-aminosalicylic acidIBA 01/2023 - 01/2009
25	HLA-DRB1 Chains (HLA DRB1)IBA 12/2022 - 01/2004
24	EpitopesIBA 01/2023 - 06/2004
18	AntigensIBA 01/2023 - 01/2004
14	Methotrexate (Mexate)FDA LinkGeneric 06/2023 - 02/2004
13	Immunoglobulin G (IgG)IBA 01/2024 - 06/2002
12	AutoantigensIBA 12/2018 - 01/2002
11	Rheumatoid FactorIBA 11/2023 - 06/2004
11	CitrullineIBA 11/2023 - 01/2005
10	Biomarkers (Surrogate Marker)IBA 12/2018 - 05/2008
9	Collagen Type II (Type II Collagen)IBA 09/2020 - 01/2005
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2010 - 09/2003
7	Antirheumatic Agents (DMARD)IBA 03/2024 - 04/2006
7	Immunoglobulin A (IgA)IBA 01/2024 - 06/2002
7	Etanercept (Enbrel)FDA Link 11/2009 - 02/2004
6	Silicon Dioxide (Silica)FDA LinkGeneric 01/2019 - 06/2010
6	Tumor Necrosis Factor InhibitorsIBA 01/2011 - 05/2004
6	Infliximab (Remicade)FDA Link 06/2010 - 01/2005
5	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 04/2014
5	HLA-DR Antigens (HLA-DR)IBA 01/2018 - 10/2004
4	ChemokinesIBA 12/2019 - 04/2016
4	ORALIT (ORS)IBA 01/2019 - 03/2006
4	EnzymesIBA 01/2018 - 01/2005
4	cyclic citrullinated peptideIBA 09/2017 - 01/2004
4	DNA (Deoxyribonucleic Acid)IBA 09/2016 - 01/2004
4	Fibrinogen (Factor I)FDA Link 06/2015 - 05/2010
3	serum P-component (CIt)IBA 12/2021 - 01/2005
3	HLA-DQA1 antigen (HLA DQA1)IBA 01/2021 - 01/2012
3	Amino Acids FDA Link 01/2021 - 01/2012
3	HLA-B Antigens (HLA-B)IBA 01/2021 - 01/2012
3	SmokeIBA 01/2019 - 01/2011
3	C-Reactive ProteinIBA 01/2018 - 01/2016
3	ametantrone (HAQ)IBA 09/2017 - 08/2014
3	TNF Receptor-Associated Factor 1IBA 02/2011 - 09/2007
3	CytokinesIBA 07/2010 - 12/2005
2	COVID-19 VaccinesIBA 03/2024 - 11/2023
2	Antigen-Antibody Complex (Immune Complex)IBA 11/2023 - 04/2009
2	Immunoglobulin M (IgM)IBA 11/2023 - 01/2007
2	Malondialdehyde (Propanedial)IBA 11/2023 - 11/2017
2	Janus Kinase InhibitorsIBA 11/2023 - 12/2021
2	Abatacept (Orencia)FDA Link 11/2023 - 08/2013
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 12/2021
2	Arginine (L-Arginine)FDA Link 01/2023 - 01/2008
2	Monoclonal AntibodiesIBA 01/2022 - 01/2019
2	HLA-A Antigens (HLA-A)IBA 01/2021 - 01/2012
2	HLA-DPB1 antigen (HLA DPB1)IBA 01/2021 - 01/2012
2	Interleukin-8 (Interleukin 8)IBA 12/2019 - 02/2017
2	LipidsIBA 01/2019 - 09/2003
2	Messenger RNA (mRNA)IBA 01/2018 - 01/2006
2	Protein-Arginine DeiminasesIBA 01/2018 - 11/2012
2	Prednisolone (Predate)FDA LinkGeneric 05/2015 - 01/2004
2	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2013 - 01/2007
2	Phosphopyruvate Hydratase (Enolase)IBA 05/2013 - 12/2009
2	VimentinIBA 05/2013 - 01/2008
2	Mineral Oil (Liquid Paraffin)FDA LinkGeneric 02/2012 - 01/2005
2	Prostaglandin-E SynthasesIBA 08/2011 - 11/2005
2	golimumab FDA Link 06/2010 - 01/2010
2	Interferon-gamma (Interferon, gamma)IBA 12/2009 - 05/2005
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 09/2007 - 09/2003
2	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2006 - 02/2004
2	triamcinolone hexacetonide (Aristospan)FDA Link 05/2006 - 12/2005
2	OilsIBA 01/2005 - 01/2002
2	MineralsIBA 01/2005 - 01/2002

Therapy/Procedure

18	Therapeutics 01/2021 - 05/2004
3	Aftercare (After-Treatment) 01/2017 - 10/2006
2	Duration of Therapy 10/2007 - 06/2003